Skip to content

RadNet

US · RDNT #2019 by market cap Listed 1970
69.71 +0.20 +0.29%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 5.37 Expensive vs history 69th percentile
5-year average 4.82 · #26 of 41 in Diagnostics & Research
P/E ratio -263.52 Cheap vs history 27th percentile
5-year average 10.31 · forward 144.58
P/S ratio 2.52 Expensive vs history 70th percentile
5-year average 1.90 · forward 2.17 · #16 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
RadNet (RDNT) 5.49B -240.38 4.90 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value75.26 Economic moatNarrow UncertaintyHigh

Trading 8.0% below Morningstar's fair value estimate.

Fair value

RadNet Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $75.26 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability undermines our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 0.8%, which ranks in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

The company's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, lies in the top 40% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

RadNet discussion 0 comments

Add a comment